People | October 27, 2022
Robert M. Davis is the new Chairman of Merck
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
Acquisition expands Merck’s growing hematology portfolio
This recognition marks the third time in five years that Merck has been included on Fortune’s Change the World list.
Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)